Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beam TherapeuticsBEAM +1.19%71 PB Ratio is 2.67 as of Aug. 07, 2026, which is 5% below its 10-year median of 2.81. GuruFocus rates BEAM with a GF Score™ of 71/100 and a GF Value™ of $28.11 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Beam Therapeutics ranks better than 53.09% on this metric.
The historical rank and industry rank for Beam Therapeutics's PB Ratio or its related term are showing as below:
BEAM'
s PB Ratio Range Over the Past 10 Years
Min: 1.37 Med: 2.81 Max: 7.44
Current: 2.67
During the past 9 years, Beam Therapeutics's highest PB Ratio was 7.44. The lowest was 1.37. And the median was 2.81.
BEAM's PB Ratio is ranked better than 53.09% of 1228
companies
in the Biotechnology industry
Industry Median: 2.905
vs BEAM: 2.67
During the past 12 months, Beam Therapeutics's average Book Value Per Share Growth Rate was -0.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.40% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Beam Therapeutics was 41.00% per year. The lowest was -10.10% per year. And the median was 5.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Beam Therapeutics PB Ratio Related Terms
Beam Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Beam Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Beam Therapeutics (BEAM) has a PB Ratio of 2.67 as of Aug. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Beam Therapeutics and its competitors. This is near median its historical median of 2.81. Over the past decade, Beam Therapeutics' PB Ratio has ranged from 1.37 to 7.44. According to the industry distribution chart, Beam Therapeutics ranks #576 out of 1228 companies in the Biotechnology industry, placing it in the top 46.9%.
Is Beam Therapeutics' PB Ratio too high?
Beam Therapeutics' current PB Ratio of 2.67 is near median its 10-year median of 2.81. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 7.44. The Biotechnology industry median PB Ratio is 2.91. Beam Therapeutics' value of 2.67 is 8.1% below this industry median. Based on the distribution chart, Beam Therapeutics ranks #576 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' PB Ratio compare to KOD and TARS?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #576 out of 1228 companies for PB Ratio. This puts Beam Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.91. Beam Therapeutics' value of 2.67 is 8.1% below this benchmark. Historically, Beam Therapeutics' own PB Ratio has ranged from 1.37 to 7.44 over the past decade. While the company's 10-year median is 2.81 vs. the industry median of 2.91, Beam Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beam Therapeutics's current PB Ratio of 2.67 is 8.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Beam Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beam Therapeutics's current PB Ratio is 2.67, which is near median its own 10-year median of 2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $28.11, compared to a current price of $27.57 — trading 1.9% below its estimated fair value. The current PB Ratio is 2.67, which is near median its 10-year median of 2.81 and 8.1% below the Biotechnology industry median of 2.91. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current PB Ratio is 2.67 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued.
The current stock price of $27.57 is trading 1.9% below its estimated GF Value™ of $28.11.
GuruFocus considers Beam Therapeutics to be Fairly Valued.
Key valuation signals for BEAM:
PB Ratio: 2.67 (near median its 10-year median of 2.81)
GF Value™: $28.11 vs. price of $27.57 (1.9% below fair value)
Industry Position: 8.1% below the Biotechnology median (#576 of 1228)
No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score
Get the complete analysis for BEAM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEAM has been successfully added to your 
